Table 1 Baseline characteristics in 22 patients. Values are reported as frequency (n [%]) or as mean (range)
Characteristic | Number of patients (percent) |
|---|---|
Age, yrs | |
Median age (range) | 55 (39–77) |
≤ 55 | 12 (54.5) |
> 55 | 10 (45.5) |
Primary tumor location | |
Ovary | 21 (95.5) |
Fallopian tube | 1 (4.5) |
International FIGO stage | |
II | 2 (9.1) |
III | 11 (50.0) |
IV | 8 (36.4) |
Unknown | 1 (4.5) |
Histological type | |
High-grade serous | 19 (86.4) |
Low-grade serous | 1 (4.5) |
Other | 1 (4.5) |
Unknown | 1 (4.5) |
Family history of cancer | |
Yes | 9 (40.9) |
No | 13 (59.1) |
ECOG | |
0 | 8 (36.4) |
1 | 13 (59.1) |
2 | 1 (4.5) |
Baseline body weight | |
≥ 77 kg | 0 (0) |
< 77 kg | 22 (100) |
Platelet count | |
≥ 150 × 109/L | 12 (54.5) |
< 150 × 109/L | 10 (45.5) |
HRD status | |
HRD-positive | 6 (27.3) |
BRCA-mutated | 1 (4.5) |
BRCA-wild type or BRCA-unknown and HRD-positive | 5 (22.7) |
HRD-negative | 8 (36.4) |
HRD unknown | 8 (36.4) |
Prior lines of chemotherapy | |
≤ 1 | 12 (54.5) |
> 1 | 10 (45.5) |
Platinum status | |
Platinum-sensitive | 5 (22.7) |
Platinum-resistant | 5 (22.7) |
Unknown | 12 (54.5) |
Categories of therapy | |
First-line maintenance therapy | 6 (27.3) |
Exploratory therapy | 16 (72.7) |
Exploratory second-line maintenance therapy | 1 (4.5) |
Exploratory front-line therapy | 6 (27.3) |
Exploratory multi-line therapy | 9 (40.9) |
NACT+IDS | |
Yes | 7 (31.8) |
No | 15 (68.2) |
Primary debulking surgery | |
Yes | 12 (54.5) |
No | 10 (45.5) |
Secondary cytoreductive surgery | |
Yes | 3 (13.6) |
No | 19 (86.4) |
Combination with other agents | |
Yes | 4 (18.2) |
No | 18 (81.8) |